<DOC>
	<DOCNO>NCT00365716</DOCNO>
	<brief_summary>This study conduct 2 part . Part A randomized , double-blind , placebo-controlled , multicenter , sequential dose-escalating evaluation . Part B randomize , double-blind ( operate in-house blinding procedure ) , placebo-controlled , multicenter , dose-ranging study .</brief_summary>
	<brief_title>Dose-Ranging Study Quadrivalent Human Papillomavirus ( HPV ) ( Types 6,11,16,18 ) L1 Virus-Like Particle ( VLP ) Vaccine ( V501-007 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Genital Diseases , Female</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female 16 23 year age Not pregnant enrollment must agree use effective contraception Month 7 study Lifetime history 0 4 male sexual partner ( individual penetrative sexual intercourse occur ) No prior receipt Human Papillomavirus ( HPV ) vaccine No receipt inactivate recombinant vaccine within 14 day prior enrollment receipt live vaccine within 21 day prior enrollment No prior abnormal Pap test show squamous intraepithelial lesion ( SIL ) biopsy show cervical intraepithelial neoplasia ( CIN ) No prior history genital wart treatment genital wart</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HPV 6/11/16/18 infection relate genital disease</keyword>
</DOC>